Hillhouse Emerges as One of Several Bidders for Everlife in Potential $1 Billion Transaction

Hillhouse Capital is among multiple parties exploring a purchase of Everlife – the Asia-focused diagnostics and healthcare-services platform owned by private equity firm Everstone – in a process that could value the business at roughly $1 billion, according to people familiar with the discussions. The reported interest from a major Asia-based investor highlights renewed momentum among financiers and strategic acquirers targeting diagnostics, laboratory networks and medical distribution across the region. Everstone, which has been actively rationalising its holdings and evaluating exits from mature assets, has engaged advisers to run a potential sale process, though sources caution talks are ongoing and no agreement has been finalised.

Why Hillhouse’s Interest Matters: A Renewed Wave of Private Equity Investment in Asian Healthcare

Market observers view Hillhouse’s approach to Everstone as indicative of a broader shift in private equity strategy toward scalable, multi-country healthcare platforms in Asia. Rather than single-market, capital-intensive plays, investors are now favouring roll-up and platform strategies that combine distribution, lab services and specialised offerings to create region-wide businesses with operational leverage.

Several structural trends are drawing attention: sustained demand for diagnostic and outpatient services after the pandemic; gaps in capacity across secondary cities; improving insurance coverage in many markets; and opportunities to lift margins through standardisation and digitalisation. Investment committees are prioritising targets that can deliver cross-border growth while remaining relatively asset-light.

Investor priorities in the region

• Multi-country reach in fast-growing South and Southeast Asian markets
• Service models that minimise capital intensity-diagnostics, medtech distribution, outsourcing
• Defensible, recurring cash flows underpinned by rising insurer and government healthcare spend
• Technology-enabled operations that shorten turnaround times and strengthen supply-chain transparency

How Dealmakers Are Thinking About Structure, Regulation and Execution Risk

Buyers and advisers are evaluating offers not just on headline price but on how bids address financing stress in a higher-rate environment and regulatory complexity for cross-border health assets. Bidders are modelling outcomes that factor in tighter data-protection regimes, increased scrutiny of medical-device approvals, and the prospect of protracted antitrust reviews in markets such as India, Singapore and Indonesia.

To bridge valuation gaps and insulate against timing or compliance risks, deal teams are considering hybrid financing and risk-sharing tools. Typical elements being discussed include:

• Blended debt-equity structures to absorb interest-rate volatility and potential close delays
• Performance-based earn-outs tied to EBITDA growth or the addition of institutional contracts
• Country-specific holding vehicles to ring-fence regulatory and currency exposures
• Co-investment tranches for regional partners with licensing and operating expertise

Success will depend on how well a buyer can leverage Everlife’s footprint across key Asian healthcare hubs. Performance varies by country, so granular, jurisdiction-level growth and margin assumptions will be central to any winning bid.

Regional dynamics shaping the auction

• India – expansion into tier-2 and tier-3 cities for diagnostics; regulators focused on price controls and device registrations
• Southeast Asia – rising demand for outsourced hospital lab services; licensing and foreign-ownership rules are important considerations
• Greater China – niche and specialised testing opportunities; heightened data-security and import approval requirements

How Sellers and Buyers Can Maximise Value and Reduce Execution Risk

To achieve premium pricing, Everstone and prospective acquirers must present a credible, repeatable growth story for Everlife that extends beyond top-line and EBITDA figures. That requires transparent disclosure on contract pipelines, payer mix, clinical quality, and local regulatory headwinds. Investors will probe client churn, pricing power in specialty diagnostics, and the durability of institutional relationships.

Key actions that enhance valuation certainty include:

• Detailed margin mapping by service line and country to identify highest-return capital deployment
• Regulatory and compliance heat-maps for targeted jurisdictions to anticipate approval timelines
• Comprehensive digital integration plans to improve utilisation and reduce per-test costs
• Supply-chain contingency measures to mitigate FX exposure and procurement shocks
• Governance and key-person risk plans to secure continuity in clinical and commercial leadership

Practical levers for value creation

• Network rationalisation: focus on cluster growth in higher-yield cities to cut underperforming locations
• Service mix optimisation: shift toward higher-acuity, higher-margin diagnostics and specialised consumables
• Unified IT and data platforms: drive efficiency, reduce integration risk and support regulatory compliance
• Long-term contracts with payers and hospitals: smooth revenue volatility and improve visibility

Context: Why Asian Healthcare Platforms Are Attractive Now

Across Asia, healthcare demand continues to expand due to demographic change, rising middle-class health consumption and increased public and private financing. While exact figures vary by market, industry research through 2023-24 showed healthcare spending in many Asian economies growing faster than GDP, and diagnostics emerging as one of the faster-growing subsectors as countries increase screening and outpatient care capacity.

For example, operators that have pursued buy-and-build strategies-consolidating smaller laboratory operators into integrated regional networks-have been able to lower unit costs and improve bargaining power with suppliers and payers within 24-36 months. Similar approaches are now being applied to medtech distribution and outsourced clinical services.

Outlook and Next Steps

If Hillhouse or another bidder secures Everlife, the new owner could accelerate regional consolidation and digital transformation across the group at a time when demand for diagnostics and outsourced health services is climbing. That said, the process remains fluid: rival bidders remain active, regulatory and financing conditions can shift, and no party has publicly confirmed terms.

Until a definitive agreement is announced, the market will be watching closely – both for signals about investor appetite for Asia’s healthcare platforms and for how strategic buyers and financial sponsors structure deals to manage cross-border regulatory and execution risks.